Interest in determining whether ERβ2/βcx is expressed in breast and other cancers has been fuelled by studies using transfected cells that have claimed that coexpression of ERβ2/βcx with ERα results in reduced activation of ERE-containing reporter constructs (Ogawa et al, 1998b; Peng et al, 2003). This evidence concerns the gene ERAL1 and cancer.